Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage (Q24248677)

29 July 2017

1 reference

title

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage (English)

1 reference

29 July 2017

0 references

4

Ale Algra

A Algra

1 reference

29 July 2017

1

Y B Roos

Yvo B.W.E.M. Roos

Y B W E M Roos

1 reference

29 July 2017

2

G J Rinkel

Gabriel JE Rinkel

G J E Rinkel

1 reference

29 July 2017

Marinus Vermeulen

3

1 reference

PubMed ID

10796425

29 July 2017

Jan van Gijn

series ordinal

5

1 reference

PubMed ID

10796425

29 July 2017

language of work or name

English

0 references

publication date

22 April 2003

0 references

1 January 2000

1 reference

PubMed ID

10796425

Cochrane Database of Systematic Reviews

29 July 2017

2003

0 references

published in

1 reference

29 July 2017

CD001245

1 reference

29 July 2017

2

1 reference

Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: A double-blind clinical trial

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Intracranial Aneurysms and Subarachnoid Hemorrhage. A Cooperative Study. Antifibrinolytic Therapy in Recent Onset Subarachnoid Hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Antifibrinolytic treatment in subarachnoid haemorrhage: present state

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Fibrinolysis in subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Antifibrinolytic agents in subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Do antifibrinolytic agents prevent rebleeding after rupture of a cerebral aneurysm? A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Systematic review of antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Antifibrinolytic Treatment in Subarachnoid Hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Tranexamic acid in subarachnoid hemorrhage. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Spectrophotometric analysis of CSF after subarachnoid hemorrhage: limitations in the diagnosis of rebleeding

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

Rerupture of intracranial aneurysms: a clinicoanatomic study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245

7 January 2021

10.1002/14651858.CD001245

Identifiers

DOI

1 reference

29 July 2017

1 reference